Effect of Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

This study is currently recruiting participants.
Verified June 2013 by Yale University
Information provided by (Responsible Party):
Robert Sherwin, Yale University
ClinicalTrials.gov Identifier:
First received: October 26, 2011
Last updated: June 27, 2013
Last verified: June 2013

Insulin treatment often causes the blood glucose levels to fall too low. The body usually responds to low blood glucose levels by releasing hormones which act against the insulin to help correct the low blood glucose levels. However, this hormone response can be altered in people with diabetes. Currently there are no therapeutic agents that can be used to improve the recovery from hypoglycemia (low blood sugar). Naltrexone is a tablet used to help people who are addicted to alcohol or morphine-based drugs to remain drug and alcohol-free but it can also affect the levels of the hormones which are released during hypoglycemia. The aim of this study is to determine whether naltrexone can be used to improve and accelerate the recovery from hypoglycemia in patients with type 1 diabetes.

Condition Intervention
Drug: Naltrexone

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: The Effect of Opiate Blockade With Naltrexone on Counterregulatory Mechanisms in Hypoglycemia

Resource links provided by NLM:

Further study details as provided by Yale University:

Primary Outcome Measures:
  • Hormone Levels [ Time Frame: 240 minutes ] [ Designated as safety issue: No ]
    Glucagon and catecholamine levels will be measured throughout the study to assess whether there are changes during hypoglycemia with naltrexone. These levels will be checked every 30 minutes during the 240 minute study session.

Estimated Enrollment: 15
Study Start Date: August 2011
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Naltrexone
    Naltrexone 100mg for two administrations.

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • type 1 diabetes (well controlled, 2-3 hypoglycemic episodes/wk) age 18-55, BMI 18-35

Exclusion Criteria:

  • pregnancy
  • significant diabetes complications
  • liver disease, cirrhosis
  • cardiac disease
  • neurological disorder
  • autonomic neuropathy
  • kidney disease
  • lactose intolerance
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01462227

Contact: Renata Belfort de Aguiar, MD 203-785-6222 glucose.studies@yale.edu

United States, Connecticut
Yale School of Medicine Recruiting
New Haven, Connecticut, United States, 06520
Contact: Renata Belfort de Aguiar, MD    203-785-6222    glucose.studies@yale.edu   
Sub-Investigator: Renata Belfort de Aguiar, MD         
Sponsors and Collaborators
Yale University
Principal Investigator: Robert Sherwin, MD Yale School of Medicine
  More Information

No publications provided

Responsible Party: Robert Sherwin, Chief of Endocrinology, Yale University
ClinicalTrials.gov Identifier: NCT01462227     History of Changes
Other Study ID Numbers: HIC1006006927
Study First Received: October 26, 2011
Last Updated: June 27, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Yale University:
Type 1 diabetes

Additional relevant MeSH terms:
Glucose Metabolism Disorders
Metabolic Diseases
Narcotic Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on April 15, 2014